WP
RAPP

Woodline Partners’s Rapport Therapeutics RAPP Stock Holding History

Woodline Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
+97,537
New +$3.58M 0.01% 736
2025
Q3 		– Sell
-185,028
Closed -$2.1M – 1074
2025
Q2 		$2.1M Buy
185,028
+3,000
+2% +$31.8K 0.01% 717
2025
Q1 		$1.83M Buy
182,028
+498
+0.3% +$6.47K 0.01% 682
2024
Q4 		$3.22M Sell
181,530
-5,030
-3% -$111K 0.02% 575
2024
Q3 		$3.82M Buy
186,560
+15,460
+9% +$332K 0.03% 419
2024
Q2 		$3.98M Buy
+171,100
New +$3.96M 0.04% 363

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Woodline Partners's RAPP Position: Q2 2026 in Review

Woodline Partners opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 97,537 shares worth $4.06M. The stake represents 0.01% of the portfolio and ranks #736 among its holdings. This is a return to the name: Woodline Partners previously reported a position in RAPP as recently as Q2 2025.

Woodline Partners first reported a position in RAPP in Q2 2024 and has held it in 6 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Woodline Partners held 97,537 shares of Rapport Therapeutics worth $4.06M as of Q2 2026.
  • Rapport Therapeutics was a new Woodline Partners position in Q2 2026.
  • Rapport Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #736 holding.
  • Woodline Partners first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.